United States Dermatomyositis Drug Market Report 2017

Publisher Name :
Date: 20-Dec-2017
No. of pages: 114
Inquire Before Buying

In this report, the United States Dermatomyositis Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

- The West

- Southwest

- The Middle Atlantic

- New England

- The South

- The Midwest

with sales (volume), revenue (value), market share and growth rate of Dermatomyositis Drug in these regions, from 2012 to 2022 (forecast).

United States Dermatomyositis Drug market competition by top manufacturers/players, with Dermatomyositis Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

- MedImmune LLC

- Neovacs SA

- Novartis AG

- Octapharma AG

- Pfizer Inc

- Eli Lilly and Company

- F. Hoffmann-La Roche Ltd

- Hope Pharmaceuticals Inc

- Idera Pharmaceuticals Inc

- KPI Therapeutics Inc

- Marathon Pharmaceuticals LLC

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

- Abatacept

- Baricitinib

- Dalazatide

- Immune Globulin

- IMO-8400

- Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

- Hospital

- Clinic

- Others

If you have any special requirements, please let us know and we will offer you the report as you want.

United States Dermatomyositis Drug Market Report 2017

Table of Contents
United States Dermatomyositis Drug Market Report 2017
1 Dermatomyositis Drug Overview
1.1 Product Overview and Scope of Dermatomyositis Drug
1.2 Classification of Dermatomyositis Drug by Product Category
1.2.1 United States Dermatomyositis Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Dermatomyositis Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Abatacept
1.2.4 Baricitinib
1.2.5 Dalazatide
1.2.6 Immune Globulin
1.2.7 IMO-8400
1.2.8 Others
1.3 United States Dermatomyositis Drug Market by Application/End Users
1.3.1 United States Dermatomyositis Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 United States Dermatomyositis Drug Market by Region
1.4.1 United States Dermatomyositis Drug Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Dermatomyositis Drug Status and Prospect (2012-2022)
1.4.3 Southwest Dermatomyositis Drug Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Dermatomyositis Drug Status and Prospect (2012-2022)
1.4.5 New England Dermatomyositis Drug Status and Prospect (2012-2022)
1.4.6 The South Dermatomyositis Drug Status and Prospect (2012-2022)
1.4.7 The Midwest Dermatomyositis Drug Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Dermatomyositis Drug (2012-2022)
1.5.1 United States Dermatomyositis Drug Sales and Growth Rate (2012-2022)
1.5.2 United States Dermatomyositis Drug Revenue and Growth Rate (2012-2022)
2 United States Dermatomyositis Drug Market Competition by Players/Suppliers
2.1 United States Dermatomyositis Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Dermatomyositis Drug Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Dermatomyositis Drug Average Price by Players/Suppliers (2012-2017)
2.4 United States Dermatomyositis Drug Market Competitive Situation and Trends
2.4.1 United States Dermatomyositis Drug Market Concentration Rate
2.4.2 United States Dermatomyositis Drug Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Dermatomyositis Drug Manufacturing Base Distribution, Sales Area, Product Type
3 United States Dermatomyositis Drug Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Dermatomyositis Drug Sales and Market Share by Region (2012-2017)
3.2 United States Dermatomyositis Drug Revenue and Market Share by Region (2012-2017)
3.3 United States Dermatomyositis Drug Price by Region (2012-2017)
4 United States Dermatomyositis Drug Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Dermatomyositis Drug Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Dermatomyositis Drug Revenue and Market Share by Type (2012-2017)
4.3 United States Dermatomyositis Drug Price by Type (2012-2017)
4.4 United States Dermatomyositis Drug Sales Growth Rate by Type (2012-2017)
5 United States Dermatomyositis Drug Sales (Volume) by Application (2012-2017)
5.1 United States Dermatomyositis Drug Sales and Market Share by Application (2012-2017)
5.2 United States Dermatomyositis Drug Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Dermatomyositis Drug Players/Suppliers Profiles and Sales Data
6.1 MedImmune LLC
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Dermatomyositis Drug Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Neovacs SA
6.2.2 Dermatomyositis Drug Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Neovacs SA Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Novartis AG
6.3.2 Dermatomyositis Drug Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Novartis AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Octapharma AG
6.4.2 Dermatomyositis Drug Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Pfizer Inc
6.5.2 Dermatomyositis Drug Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Eli Lilly and Company
6.6.2 Dermatomyositis Drug Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 F. Hoffmann-La Roche Ltd
6.7.2 Dermatomyositis Drug Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Hope Pharmaceuticals Inc
6.8.2 Dermatomyositis Drug Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Idera Pharmaceuticals Inc
6.9.2 Dermatomyositis Drug Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 KPI Therapeutics Inc
6.10.2 Dermatomyositis Drug Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Marathon Pharmaceuticals LLC
7 Dermatomyositis Drug Manufacturing Cost Analysis
7.1 Dermatomyositis Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Dermatomyositis Drug
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Dermatomyositis Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Dermatomyositis Drug Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Dermatomyositis Drug Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Dermatomyositis Drug Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Dermatomyositis Drug Sales Volume Forecast by Type (2017-2022)
11.3 United States Dermatomyositis Drug Sales Volume Forecast by Application (2017-2022)
11.4 United States Dermatomyositis Drug Sales Volume Forecast by Region (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
List of Tables and Figures
Figure Product Picture of Dermatomyositis Drug
Figure United States Dermatomyositis Drug Market Size (K Pcs) by Type (2012-2022)
Figure United States Dermatomyositis Drug Sales Volume Market Share by Type (Product Category) in 2016
Figure Abatacept Product Picture
Figure Baricitinib Product Picture
Figure Dalazatide Product Picture
Figure Immune Globulin Product Picture
Figure IMO-8400 Product Picture
Figure Others Product Picture
Figure United States Dermatomyositis Drug Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Dermatomyositis Drug by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Dermatomyositis Drug Market Size (Million USD) by Region (2012-2022)
Figure The West Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Dermatomyositis Drug Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Dermatomyositis Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Dermatomyositis Drug Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Dermatomyositis Drug Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Dermatomyositis Drug Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Dermatomyositis Drug Sales Share by Players/Suppliers
Figure 2017 United States Dermatomyositis Drug Sales Share by Players/Suppliers
Figure United States Dermatomyositis Drug Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Dermatomyositis Drug Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Dermatomyositis Drug Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Dermatomyositis Drug Revenue Share by Players/Suppliers
Figure 2017 United States Dermatomyositis Drug Revenue Share by Players/Suppliers
Table United States Market Dermatomyositis Drug Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Dermatomyositis Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Dermatomyositis Drug Market Share of Top 3 Players/Suppliers
Figure United States Dermatomyositis Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Dermatomyositis Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Dermatomyositis Drug Product Category
Table United States Dermatomyositis Drug Sales (K Pcs) by Region (2012-2017)
Table United States Dermatomyositis Drug Sales Share by Region (2012-2017)
Figure United States Dermatomyositis Drug Sales Share by Region (2012-2017)
Figure United States Dermatomyositis Drug Sales Market Share by Region in 2016
Table United States Dermatomyositis Drug Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Dermatomyositis Drug Revenue Share by Region (2012-2017)
Figure United States Dermatomyositis Drug Revenue Market Share by Region (2012-2017)
Figure United States Dermatomyositis Drug Revenue Market Share by Region in 2016
Table United States Dermatomyositis Drug Price (USD/Pcs) by Region (2012-2017)
Table United States Dermatomyositis Drug Sales (K Pcs) by Type (2012-2017)
Table United States Dermatomyositis Drug Sales Share by Type (2012-2017)
Figure United States Dermatomyositis Drug Sales Share by Type (2012-2017)
Figure United States Dermatomyositis Drug Sales Market Share by Type in 2016
Table United States Dermatomyositis Drug Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Dermatomyositis Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Dermatomyositis Drug by Type (2012-2017)
Figure Revenue Market Share of Dermatomyositis Drug by Type in 2016
Table United States Dermatomyositis Drug Price (USD/Pcs) by Types (2012-2017)
Figure United States Dermatomyositis Drug Sales Growth Rate by Type (2012-2017)
Table United States Dermatomyositis Drug Sales (K Pcs) by Application (2012-2017)
Table United States Dermatomyositis Drug Sales Market Share by Application (2012-2017)
Figure United States Dermatomyositis Drug Sales Market Share by Application (2012-2017)
Figure United States Dermatomyositis Drug Sales Market Share by Application in 2016
Table United States Dermatomyositis Drug Sales Growth Rate by Application (2012-2017)
Figure United States Dermatomyositis Drug Sales Growth Rate by Application (2012-2017)
Table MedImmune LLC Basic Information List
Table MedImmune LLC Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure MedImmune LLC Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure MedImmune LLC Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure MedImmune LLC Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Neovacs SA Basic Information List
Table Neovacs SA Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Neovacs SA Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Neovacs SA Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Neovacs SA Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Novartis AG Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Novartis AG Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Novartis AG Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Octapharma AG Basic Information List
Table Octapharma AG Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Octapharma AG Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Octapharma AG Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Octapharma AG Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Pfizer Inc Basic Information List
Table Pfizer Inc Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Pfizer Inc Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Pfizer Inc Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Pfizer Inc Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Eli Lilly and Company Basic Information List
Table Eli Lilly and Company Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly and Company Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Eli Lilly and Company Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Eli Lilly and Company Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table F. Hoffmann-La Roche Ltd Basic Information List
Table F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure F. Hoffmann-La Roche Ltd Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Hope Pharmaceuticals Inc Basic Information List
Table Hope Pharmaceuticals Inc Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Hope Pharmaceuticals Inc Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Hope Pharmaceuticals Inc Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Hope Pharmaceuticals Inc Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Idera Pharmaceuticals Inc Basic Information List
Table Idera Pharmaceuticals Inc Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Idera Pharmaceuticals Inc Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure Idera Pharmaceuticals Inc Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure Idera Pharmaceuticals Inc Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table KPI Therapeutics Inc Basic Information List
Table KPI Therapeutics Inc Dermatomyositis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure KPI Therapeutics Inc Dermatomyositis Drug Sales Growth Rate (2012-2017)
Figure KPI Therapeutics Inc Dermatomyositis Drug Sales Market Share in United States (2012-2017)
Figure KPI Therapeutics Inc Dermatomyositis Drug Revenue Market Share in United States (2012-2017)
Table Marathon Pharmaceuticals LLC Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Dermatomyositis Drug
Figure Manufacturing Process Analysis of Dermatomyositis Drug
Figure Dermatomyositis Drug Industrial Chain Analysis
Table Raw Materials Sources of Dermatomyositis Drug Major Players/Suppliers in 2016
Table Major Buyers of Dermatomyositis Drug
Table Distributors/Traders List
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Dermatomyositis Drug Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Dermatomyositis Drug Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Dermatomyositis Drug Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Dermatomyositis Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Dermatomyositis Drug Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global Platinum based Cancer Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 122
    Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. They are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, popular drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. Scope of the Report: This report focuses on the Platinum based Cancer Drug......
  • Global IGY Polyclonal Antibodies Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 120
    Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is also found in high concentrations in chicken egg yolk. As with the other immunoglobulins, IgY is a class of proteins which are formed by the immune system in reaction to certain foreign substances, and specifically recognize them. IgY antibodies have a different structure from IgG, particularly in the Fc and hinge regions. The affinity maturation proces......
  • Global Hypromellose Acetate Succinate Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 119
    Hypromellose acetate succinate is an enteric coating material which was first approved in Japan in 1987. As of January 2004, this product has been approved in Korea, several countries in Europe, and USA as well as in Japan. Scope of the Report: This report focuses on the Hypromellose Acetate Succinate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manuf......
  • Global Humira Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 121
    Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa. Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis. ......
  • Global Hemostasis and Tissue Sealing Agents Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 136
    Hemostasis is a process which causes bleeding to stop, meaning to keep blood within a damaged blood vessel (the opposite of hemostasis is hemorrhage). It is the first stage of wound healing. Tissue sealing agents are used during medical procedures to achieve hemostasis. They vary based on their mechanism of action, composition, ease of application, adherence to tissue, immunogenicity and cost. These agents permit rapid hemostasis, better Visualization of the surgical area, shorter operati......
  • Global Darbepoetin Alfa Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 124
    Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and ......
  • Global Cannabis Oil Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 124
    Cannabis oil is from the marijuana plant (cannabis indicas). The oil is extracted from the leaves of the cannabis plant. It contains high levels of THC. It is used for medicinal purposes and as a recreational drug. Cannabis oil reached considerable popularity when a man in Canada named Rick Simpson began distributing this concentrate, albeit illegally, as a medicine. Rick's oil (commonly known as "Rick Simpson oil") brought the long studied knowledge about the anti-tumor and various medi......
  • Global Anti-infective Ophthalmic Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Aug-2018        Price: US 3480 Onwards        Pages: 122
    Ophthalmic anti-infectives are anti-infectives contained in a product formulated especially to be instilled or applied in the eye or eyes. Ophthalmic anti-infectives include eyedrops, gels or ointments. Anti-infectives are drugs that can either kill an infectious agent or inhibit it from spreading. Anti-infectives include antibiotics and antibacterials, antifungals, antivirals and antiprotozoals. Scope of the Report: This report focuses on the Anti-infective Ophthal......
  • Global Tracheotomy Tube Market Professional Survey Report 2018
    Published: 20-Aug-2018        Price: US 3500 Onwards        Pages: 116
    This report studies the global Tracheotomy Tube market status and forecast, categorizes the global Tracheotomy Tube market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). Tracheostomy Tube is inserted through a surgical opening (stoma) of the trachea to secure an airway during breath......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs